Navigation Links
Statement on FDA's Approval of XENAZINE(R) for the Treatment of Chorea Associated With Huntington's Disease
Date:8/15/2008

NEW YORK, Aug. 15 /PRNewswire/ -- The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease.

"Chorea is a major cause of disability and death in patients with Huntington's disease. Chorea is not just a mere inconvenience; it can prevent Huntington's disease patients from walking, talking, working, watching television and almost every aspect of one's life. We are ecstatic that, through the approval of Xenazine, patients and families will have the option to take the only drug developed specifically for treating the movements of Huntington's disease," said Nancy Wexler, Ph.D., Higgins Professor of Neuropsychology in the departments of neurology and psychiatry at Columbia University and president of the Hereditary Disease Foundation.

"While we are still hopeful we can some day find a cure, the approval of Xenazine is a breakthrough for the Huntington's disease community," said Dr. Wexler.

The approval of Xenazine marks the first and only FDA-approved treatment for any symptom of Huntington's disease.


'/>"/>
SOURCE Hereditary Disease Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Statement by the Service Employees International Union (SEIU) Concerning Allegations About SEIU Local 6434, United Long Term Care Workers Union
2. Statement of concern on detention of Drs. Kamiar and Arash Alaei by Iranian authorities
3. Statement by Alan Lambert, Scout Executive, National Capital Area Council, Boy Scouts of America (NCAC) Concerning Closure of Goshen Scout Reservation August 3, 2008
4. Pelosi Statement on Congress Sending Consumer Product Safety Legislation to President
5. PCMA Statement on Baucus-Conrad Comparative Effectiveness Legislation
6. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
7. Pelosi Statement on House Passage of Global AIDS Legislation
8. Cord Blood America CEO Announces Statement Regarding Expansion and Company Valuation
9. Statement Regarding Los Angeles City Attorney Enforcement Action
10. Pelosi Statement on the Death of Dr. Michael DeBakey
11. Newt Gingrich Statement on the Loss of Tony Snow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: